<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675372</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-XWAD-202008-12</org_study_id>
    <nct_id>NCT04675372</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Facilitate Analgesia</brief_title>
  <official_title>Based on the Real-time Monitoring of Nociceptive Index, Dexmedetomidine as a Neuraxial Adjuvant Facilitate Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China International Neuroscience Institution</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China International Neuroscience Institution</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-clinic evidences showed that DEX produces antinociception by inhibiting the activation of&#xD;
      spinal microglia and astrocyte decreasing noxious stimuli evoked release of nociceptive&#xD;
      substances and further interrupting the spinal neuron-glia cross talk and regulating the&#xD;
      nociceptive transmission under chronic pain condition. in this study, the analgesic efficacy&#xD;
      of Dexmedetomidine was evaluated by a new non-invasive nociceptive index (qNOX). In this&#xD;
      study, Anagel6000 analgesia monitor was used to quantitatively compare the analgesic efficacy&#xD;
      of Dexmedetomidine compared with Midazolam.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre-clinic evidences showed that DEX produces antinociception by inhibiting the activation of&#xD;
      spinal microglia and astrocyte decreasing noxious stimuli evoked release of nociceptive&#xD;
      substances and further interrupting the spinal neuron-glia cross talk and regulating the&#xD;
      nociceptive transmission under chronic pain condition. in this study, the analgesic efficacy&#xD;
      of Dexmedetomidine was evaluated by a new non-invasive nociceptive index (qNOX). In this&#xD;
      study, Anagel6000 analgesia monitor was used to quantitatively compare the analgesic efficacy&#xD;
      of Dexmedetomidine compared with Midazolam.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 19, 2021</start_date>
  <completion_date type="Actual">August 3, 2021</completion_date>
  <primary_completion_date type="Actual">August 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>nociceptive index</measure>
    <time_frame>During operation</time_frame>
    <description>qNOX reached target 80 during drug infusion（qNOX&lt;80 Adequate；qNOX&gt;80 unadequate）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hypoxemia</measure>
    <time_frame>During operation</time_frame>
    <description>incidence of hypoxemia(SPO2&lt;95%Mild hypoxemia,SPO2&lt;90% moderate hypoxemia, SPO2&lt;85% severe hypoxemia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systolic blood pressure</measure>
    <time_frame>During operation</time_frame>
    <description>Change of systolic blood pressure(SBP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>During operation</time_frame>
    <description>fluctuation of heart rate(HR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic blood pressure</measure>
    <time_frame>During operation</time_frame>
    <description>fluctuation of diastolic blood pressure(DBP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>muscular activity</measure>
    <time_frame>During operation</time_frame>
    <description>fluctuation of muscular activity (EMG)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Lower Limb Fracture</condition>
  <condition>Nerve Block</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine group (Group DEX) was given 1.5ug/kg/h Dexmedetomidine continuous infusion Dexmedetomidine group (Group DEX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam group (Group MID) was continuously pumped with 0.05mg/kg/h midazolam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine group (Group D) was given 1.5ug/kg/h Dexmedetomidine continuous infusion</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam group (Group M) was continuously pumped with 0.05mg/kg/h midazolam</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged from 18 to 80 years old&#xD;
&#xD;
          -  American Association of anesthesiologists (ASA) grade Ⅱ ~ IV&#xD;
&#xD;
          -  body mass index (BMI) 18.5-40&#xD;
&#xD;
          -  planning undergoing peripheral nerve block&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  incomplete effect of nerve block&#xD;
&#xD;
          -  Alzheimer's disease&#xD;
&#xD;
          -  implanted cardiac pacemakers&#xD;
&#xD;
          -  mental illness&#xD;
&#xD;
          -  epilepsy&#xD;
&#xD;
          -  autonomic nervous system diseases&#xD;
&#xD;
          -  projected the duration of the operation was more than 3 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>China International Neuroscience</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>nociceptive index</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

